Vestmark Advisory Solutions Inc. Raises Stock Holdings in Tempus AI, Inc. (NASDAQ:TEM)

Vestmark Advisory Solutions Inc. boosted its holdings in Tempus AI, Inc. (NASDAQ:TEM - Free Report) by 148.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 122,450 shares of the company's stock after purchasing an additional 73,132 shares during the quarter. Vestmark Advisory Solutions Inc. owned about 0.08% of Tempus AI worth $4,134,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. First Horizon Advisors Inc. purchased a new stake in shares of Tempus AI in the third quarter worth approximately $30,000. FNY Investment Advisers LLC purchased a new stake in Tempus AI in the 4th quarter valued at $67,000. IFP Advisors Inc bought a new position in Tempus AI during the 4th quarter valued at $76,000. US Bancorp DE purchased a new position in Tempus AI during the 4th quarter worth $80,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in Tempus AI during the 4th quarter worth $178,000. Institutional investors own 24.22% of the company's stock.

Tempus AI Stock Down 8.0 %

Shares of TEM stock traded down $3.93 on Monday, hitting $45.17. 10,014,217 shares of the stock were exchanged, compared to its average volume of 4,809,587. Tempus AI, Inc. has a one year low of $22.89 and a one year high of $91.45. The firm's 50 day moving average is $54.30 and its two-hundred day moving average is $52.30. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17.

Insiders Place Their Bets

In other Tempus AI news, EVP Andrew Polovin sold 51,504 shares of the stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $42.39, for a total value of $2,183,254.56. Following the sale, the executive vice president now directly owns 246,085 shares in the company, valued at $10,431,543.15. This represents a 17.31 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Bradley A. Keywell sold 265,000 shares of the firm's stock in a transaction on Friday, January 17th. The shares were sold at an average price of $35.10, for a total transaction of $9,301,500.00. Following the completion of the transaction, the insider now directly owns 15,218,365 shares of the company's stock, valued at approximately $534,164,611.50. The trade was a 1.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 6,406,855 shares of company stock worth $350,610,637 over the last quarter.

Remove Ads

Analyst Ratings Changes

A number of research analysts recently weighed in on TEM shares. Needham & Company LLC raised their price target on shares of Tempus AI from $56.00 to $70.00 and gave the company a "buy" rating in a research report on Tuesday, February 25th. William Blair restated a "market perform" rating on shares of Tempus AI in a research note on Tuesday, February 25th. Morgan Stanley increased their price target on Tempus AI from $50.00 to $60.00 and gave the company an "overweight" rating in a research report on Thursday. JPMorgan Chase & Co. lowered Tempus AI from an "overweight" rating to a "neutral" rating and lifted their price target for the stock from $50.00 to $55.00 in a report on Tuesday, February 25th. Finally, Wolfe Research downgraded Tempus AI from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, February 26th. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, Tempus AI presently has a consensus rating of "Moderate Buy" and a consensus target price of $61.18.

Tempus AI Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.